Omega Therapeutics (OMGAQ) Stock Price, News & Analysis

Company Overview

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.13
• 52-Week Range: $0.01 to $1.76
• Volume: 541 shs
• Average Volume: 470,823 shs
• Market Capitalization: $996.66 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

Omega Therapeutics Stock Analysis - MarketRank™

Omega Therapeutics scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Omega Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Omega Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Omega Therapeutics are expected to grow in the coming year, from ($1.25) to ($0.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Omega Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Omega Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Omega Therapeutics has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.61% of the outstanding shares of Omega Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Omega Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Omega Therapeutics has recently increased by 29.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Omega Therapeutics does not currently pay a dividend.

Dividend Growth

Omega Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.61% of the outstanding shares of Omega Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Omega Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Omega Therapeutics has recently increased by 29.46%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 4 people have searched for OMGAQ on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

2 people have added Omega Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Omega Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.50% of the stock of Omega Therapeutics is held by insiders.

Percentage Held by Institutions

97.47% of the stock of Omega Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OMGAQ Stock Analysis - Frequently Asked Questions

How have OMGAQ shares performed this year?

Omega Therapeutics' stock was trading at $0.7456 at the beginning of the year. Since then, OMGAQ stock has decreased by 97.6% and is now trading at $0.0180.

How were Omega Therapeutics' earnings last quarter?

Omega Therapeutics, Inc. (OTCMKTS:OMGAQ) announced its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The business had revenue of $2.13 million for the quarter, compared to analyst estimates of $1.25 million.

How do I buy shares of Omega Therapeutics?

Shares of OMGAQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/06/2024
• Today: 8/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:OMGAQ
• Previous Symbol: NASDAQ:OMGA
• CIK: 1850838
• Web: www.omegatherapeutics.com
• Phone: 617-949-4360
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Omega Therapeutics: $8.50
• High Price Target: $12.00
• Low Price Target: $4.00
• Potential Upside/Downside: +47,122.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.09 million
• Price / Sales: 0.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 55,370,000
• Free Float: 50,660,000
• Market Cap: $996.66 thousand
• Optionable: Optionable
• Beta: 0.57